SINPHAR — Investor Presentation 2023

Dec 13, 2023

==> picture [258 x 100] intentionally omitted <==

==> picture [149 x 100] intentionally omitted <==

==> picture [150 x 100] intentionally omitted <==

==> picture [165 x 100] intentionally omitted <==

==> picture [720 x 298] intentionally omitted <==

==> picture [219 x 88] intentionally omitted <==

==> picture [155 x 87] intentionally omitted <==

==> picture [179 x 87] intentionally omitted <==

Disclaimer

• 本簡報是建立於本公司從各項來源所取得之資訊。有些 訊可能受未來不確定性因素影響，致使與原先本公司對 於未來前景的說明迥異。未來若有變更或調整時，請以 公開資訊觀測站公告資訊為依據。

• 所涉產業為法規高度規範與高度專業領域，提醒投資人 須審慎投資。

• This presentation is based on the information obtained from various sources which the Company believes to be reliable. But at some point in the future, there are a variety of factors which could cause actual results to differ materially from those statements. Therefore, please refer to the information on MOPS website as the main basis if any adjustment has been made. (http://mops.twse.com.tw/mops/web/index)

• The industries involved are highly regulated and highly specialized fields, and investors are reminded to invest prudently.

2

Contents

1. Outlook 2. Operations

Development

3 ~~. Financial Reports~~

4. ESG 5. Social Responsibility

3

From Taiwan to the World

2000 Sinphar TPEx-listed 2002 Sinphar TWSE-listed 2014 SynCoreBio TPEx-listed

1977 2002 Established Sinphar Invested in Sinphar TianLi & Ilan, Taiwan He-Tian Tianli Generic drugs, functional food, Hangzhou ( CN ), Xinjiang(CN ) cosmetics Generic, TCM, natural products

2012

Merged ZuniMed Biotech

Nantou, Taiwan Medical devices

1997 ~~Established CanCap~~ Vancouver, Canada Clinical control for New Drug of North America, raw material sourcing

2008

~~Co-found SynCoreBio~~ Ilan, Taiwan New Drug Development

==> picture [176 x 93] intentionally omitted <==

==> picture [106 x 93] intentionally omitted <==

==> picture [98 x 93] intentionally omitted <==

==> picture [102 x 93] intentionally omitted <==

==> picture [100 x 93] intentionally omitted <==

==> picture [140 x 93] intentionally omitted <==

4

Major Developments

Diverse Development of Generic Drugs

==> picture [273 x 274] intentionally omitted <==

Value-added New Drugs R&D Comprehensive Plans for Natural Plant Extracts

5

Stride Ahead Exporting to over 10 countries/regions and increasing.

According to TFDA as of 12/1 and DCB data:

1. API manufacturer:29

2. Western medicine manufacturer:144

3. Pharmaceutical/medicinal related companies: over 100

4. Medical device companies: over 10,000

==> picture [201 x 76] intentionally omitted <==

International Collaboration

Alliances

• Medical centers, hospitals and clinics

According to Ministry of Finance data, there are more than 10,500 pharmacies in Taiwan.

• 1,300 Sinphar Counters

• Drug stores/retail stores

• • Major e-commerce platforms

6

Integration of Resources

Sinphar & SynCore • Joint R & D

• Improvement in manufacturing

(Example: freeze-drying process)

• ~~Natural~~

• Sinphar & Tian ~~Li Medical~~ • Herbal Mutual benefit in Devices

• R&D achievement Extraction

• • Strategic cooperation for patented products

• (Example: obtained 4 health food permits)

Sinphar & ZuniMed ISO15378 Class 100,000 clean room

(Example: bottleware integration)

7

Management Philosophy Respecting Life and Health

Average salary per employee (in NTD)

Lanyang Mazu Cultural Celebration

Sponsors Sinphar Yilan Marathon

==> picture [242 x 133] intentionally omitted <==

----- Start of picture text -----

600,000
550,000
500,000
Jan-Sep 2021 Jan-Sep 2022 Jan-Sep 2023
----- End of picture text -----

==> picture [251 x 170] intentionally omitted <==

2023 Sinphar Yilan Marathon

==> picture [175 x 117] intentionally omitted <==

----- Start of picture text -----

Sponsors Taiwan Alzheimer’s Disease
Association
----- End of picture text -----

==> picture [179 x 90] intentionally omitted <==

==> picture [192 x 131] intentionally omitted <==

----- Start of picture text -----

Donates supplies for fighting
against Covid-19
Sinphar Biotech Camp
----- End of picture text -----

Collaborates with local government to promote chiang gu

==> picture [173 x 90] intentionally omitted <==

==> picture [174 x 126] intentionally omitted <==

----- Start of picture text -----

2023 Champion for Toucheng and
Tainan chiang gu
Excellence in Food GMP
----- End of picture text -----

8

==> picture [136 x 93] intentionally omitted <==

Comprehensive Product Line for All Ages

==> picture [331 x 351] intentionally omitted <==

----- Start of picture text -----

Dermatology Ophthalmology Pediatrics
Oncology Otolaryngology Orthopedics
Obstetrics &
General Surgery Plastic Surgery
Gynecology
Metabolism Dental Gastroenterology
Urology General Medicine Psychiatry
----- End of picture text -----

New Product Released in 2023: 3

New Product Released in 2023: 3

9

Health Around the Corner

==> picture [80 x 89] intentionally omitted <==

==> picture [349 x 367] intentionally omitted <==

==> picture [81 x 101] intentionally omitted <==

==> picture [80 x 92] intentionally omitted <==

==> picture [80 x 98] intentionally omitted <==

==> picture [111 x 64] intentionally omitted <==

==> picture [111 x 65] intentionally omitted <==

==> picture [112 x 64] intentionally omitted <==

==> picture [111 x 64] intentionally omitted <==

==> picture [112 x 63] intentionally omitted <==

==> picture [85 x 107] intentionally omitted <==

==> picture [86 x 99] intentionally omitted <==

==> picture [86 x 94] intentionally omitted <==

==> picture [86 x 94] intentionally omitted <==

==> picture [112 x 64] intentionally omitted <==

Post Pandemic Care

==> picture [91 x 124] intentionally omitted <==

==> picture [94 x 121] intentionally omitted <==

==> picture [511 x 437] intentionally omitted <==

==> picture [93 x 135] intentionally omitted <==

==> picture [96 x 120] intentionally omitted <==

==> picture [93 x 122] intentionally omitted <==

==> picture [82 x 102] intentionally omitted <==

==> picture [101 x 124] intentionally omitted <==

==> picture [84 x 115] intentionally omitted <==

11

==> picture [83 x 45] intentionally omitted <==

International Award Winning Product

==> picture [718 x 330] intentionally omitted <==

==> picture [364 x 109] intentionally omitted <==

12

13

==> picture [115 x 73] intentionally omitted <==

==> picture [289 x 54] intentionally omitted <==

經107例人體試驗 證實有感提升 ~~保護~~ *文獻發表中

==> picture [163 x 153] intentionally omitted <==

==> picture [349 x 268] intentionally omitted <==

經國際學術發表文獻證實 、 具調節免疫 緩解過敏體質雙重作用

Health Foods for Aging Society

三高全照護健康食品系列

==> picture [351 x 195] intentionally omitted <==

==> picture [720 x 192] intentionally omitted <==

Sinphar Health Park – Sharing Knowledge with the Public

1. Since the opening of the Park, approximately 80,000 people have come to understand the manufacturing process of pharmaceuticals and food products. An expansion plan is underway to accommodate the expected 60,000 visitors for 2024

2. Located near Renshan Botanical Garden and Xinliao Waterfall, this scenic and freeadmission Park is an ideal place for tourists visiting Yilan to relax and learn more about heath and well-being

==> picture [165 x 100] intentionally omitted <==

==> picture [162 x 100] intentionally omitted <==

==> picture [152 x 87] intentionally omitted <==

==> picture [156 x 90] intentionally omitted <==

16

Production Digitalization

==> picture [716 x 462] intentionally omitted <==

----- Start of picture text -----

Shipping
Production Plan Scheduling
Warehouse
MRP Create Work BI Cockpit
Order
PO
Warehouse
Receiving
ISO/IEC 27001
IQC ISMS QA
Warehouse FQC
Warehouse Weighing
Packaging
Picking MM WIP Warehouse MP WIP Warehouse
IPQC Cockpit
ERP LIMS
Production Data
APS MES
PLC & Equipment & Sensor
WMS SCADA
17
----- End of picture text -----

International Markets

Japan

• Product G, launched in 2020, steady growth

Thailand

• Product T, apply in 2024, expect to launch in 2026

• Product G, obtained license in 2023

• Product C, launched 2023, steady growth

Malaysia

• Product T, laun ~~ched in 2020, steady~~ growth

• Product S, launched in 2022, steady growth

• Product K, launched in 2021 2021, steady growth

Philippines

• Product L, applied in 2022, expect to launch in 2024

• Product G, obtained license in 2023

• Vietnam

• Product G, expect to obtain license in 2024

• Product A, applied in 2022

• Product L, applied in 2022

• ~~Product C, launched in 2023, steady~~ growth

Iraq

• Product A, applied in 2022

• Product L, applied in 2022

• Product G, applied in 2022

Indonesia

• Product B, launched in 2023, steady growth

18

Sustainability

Energy Saving

Average annual saving

2.11%

(Based on 2015-2022 verified reporting to the Bureau of Energy, Ministry of Economic Affairs, Conservation Audit Technology Information Service)

==> picture [92 x 66] intentionally omitted <==

Carbon Reducing

7.4% reduction in direct greenhouse gas emissions

4.6% reduction in sludge removal volume per month (2022 vs 2021)

19

Growth

Therapeutic Drugs

==> picture [148 x 74] intentionally omitted <==

• 3 New listings are expected in 2024

• Co-develop and manufacture with Japanese pharmaceutical companies and expand ASEAN market

• Agent to Japanese products for domestic market

• API in-depth development plan

• Establish domestic alliance

Functional Supplements

• 4 New listings are expected in 2024

• Cancer Trea ~~tment Injectable/Solid Dosage Form~~ • Expand the R&D and manufacturing capacity of cancer injectables

• Manufacture cytotoxic injectables with fully automated isolator and setup closed system solid dosage form

• MST launched in 2021; in 2023 added new indication

• Megestrol launched in 2022

Sinphar Health Park

• Co-develop with local government to setup a regional tourist attraction route

20

Cancer Drug Dosage Development

==> picture [90 x 20] intentionally omitted <==

Product	Product					Target Indication Patient (number of patients/year in Taiwan)*
	ct	Target Indication		Type	Method
SCB321		Colon Cancer Stomach Cancer		Generic Self-Developed (incl. API)		Colon Cancer: 16829/year Stomach Cancer: 4257/year
SCB211		Liver Cancer		Generic Import Liver Cancer: 10982/year
SCB311		Pancreatic Cancer GIST		Generic Import Pancreatic Cancer：3012/year
SCB171		AML		Generic Import AML: 885/year
SCB221 SCB222		CML		Generic Import CML：283/year
SCB161		Multiple M~~yeloma~~ Breast Cancer Ovarian Cancer	~~l~~	Generic ~~Self-Developed~~ (Super Generic Drug) Breast Cancer：15314/year Ovarian Cancer：1705/year
SCB181		Reduce frequency of chemotherapy-induced bone marrow suppression		New Drug Import SCLC: 396/year
SCB191		Hepatic veno-occlusive disease following tem cell transplantation		New Drug Import Leukemia and MPN：183/year Malignant Lymphoma：191/year

* Source: 2020 Ministry of Health and Welfare Cancer Report

21

Pipeline

==> picture [105 x 22] intentionally omitted <==

==> picture [709 x 417] intentionally omitted <==

----- Start of picture text -----

6
3
----- End of picture text -----

Sinphar Group's New Drug Catalog

Refer to Annual Report from Sinphar and SynCore for more details

Memoregain® SB03 Veregen TLCT Plus EGW Vascular dementia Launched in 20 Obtained license countries Sold for RMB55,000,000

SB05 PC Pancreatic Cancer Second Line Treatment:Clinical trial Phase Ⅲ First Line Treatment: NMPA approved; Phase Ⅲ clinical trial

ST01 ST02 Alzheimer's disease Chronic stable angina US/TW FDA approved US/TW FDA approved Clinical phase Ⅱ Clinical phase Ⅱ TW Health Food License Completed SB02 SB01 Cancer drug Head and neck cancer Pre-clinical formulation Clinical phase Ⅱ development

SF01 GF159 Cancer adjuvant therapy Brain health food ~~Pre-clinical research~~ Healthy people clinical completed trials completed TW Health Food License

SB04 SB05 TNBC Dry age-related macular Triple negative breast degeneration cancer Clinical phase Ⅱ / Ⅲ Clinical phase Ⅲ

23

天然資源（原料/提取物）

==> picture [181 x 149] intentionally omitted <==

==> picture [176 x 149] intentionally omitted <==

==> picture [164 x 148] intentionally omitted <==

==> picture [148 x 148] intentionally omitted <==

Memoregain® TLCT Plus 天力再生 ® 管花肉蓯蓉提取物 ( Cistanche tubulosa extract)

Lipucan[® ] 天力速康 [® ] ~~茯苓三萜菁萃物~~ (Poria cocos triterpenoids)

Protygold[® ] KAZINAKE[® ] 杏补宜 [® ] 杏补宜 [® ] ~~核桃肽 初榨核桃油~~ (Walnut oligopeptide) (Walnut Oil)

==> picture [125 x 49] intentionally omitted <==

==> picture [67 x 46] intentionally omitted <==

Organic certification

==> picture [99 x 46] intentionally omitted <==

、 、 EU Ecocert USDA Organic China Organic Food Certification Center

RD research achievements

Walnut oil won the ITQI and Monde Selection awards in 2023

==> picture [61 x 66] intentionally omitted <==

==> picture [209 x 235] intentionally omitted <==

The ingredient has been sold to 14 countries.

==> picture [71 x 71] intentionally omitted <==

Walnut oligopeptide won 4 gold and 1 silver international patent invention awards in 2022 Walnut oligopeptide obtains Nutritional Intelligence_ New Plant Power Award

SCI papers patents in countries

Differentiated Marketing

Market

• Major markets in Taiwan and China as food raw material; begin to export in 2021 now sold to 14 countries around the world

• Looking for new markets post COVID-19 pandemic

Marketing

• Provide specialized customer support with R&D and technical advantage and comprehensive supply chain

==> picture [144 x 147] intentionally omitted <==

Publish patent and research findings

Comprehensive supply chain Quality

Scientific Research Safety Toxicity and contamination tests

26

Profit/Loss

NTD in Thousand

==> picture [603 x 325] intentionally omitted <==

----- Start of picture text -----

3,000,000
2,214,367
2,094,144
2,000,000 1,792,176
1,000,000
265,321
213,378
0 (23,099)
Q1~Q3 2021 Q1~Q3 2022 Q1~Q3 2023
(1,000,000)
Revenue
Net income (loss)
----- End of picture text -----

Net income (loss) attributable to parent company’s shareholders

Sales revenue and net profit showing growing trend compared to same period from previous years.

27

Sales Revenue

NTD in Thousand

	les Revenue NTD in Thousand	les Revenue NTD in Thousand	les Revenue NTD in Thousand	les Revenue NTD in Thousand	les Revenue NTD in Thousand	les Revenue NTD in Thousand	les Revenue NTD in Thousand
0 500,000 1,000,000 1,500,000 2,000,000 2,500,000		1,792,176 2,094,144 2,214,367
				Q1-Q3 2021	Q1-Q3 2022	Q1-Q3 2023
			Taiwan	1,470,928	1,695,190	1,905,622
			China	127,988	148,683	137,435
			USA	54,071	114,723	0
			Vietnam	58,096	32,952	54,417
						~~5~~1,869
			~~Indonesia~~	~~2,081~~	~~19,850~~
			Other	79,012	82,746	65,024
			合計	1,792,176	2,094,144	2,214,367

As of Nov 2023, YTD sales was NTD 2,717,000.

28

NTD in Thousand

Ratio

==> picture [296 x 39] intentionally omitted <==

Debt Ratio (%) Current Ratio (%) Accounts Receivable Turnover Accounts Payable Turnover Inventory Turnover

==> picture [259 x 60] intentionally omitted <==

Cash and cash equivalents, end of the period Unspent bank financing

Q1~Q3 2022 Q1~Q3 2023

47.0 47.2 207.7 217.8

207.7

4.43 4.70 6.23 6.94 2.41 2.35

Sinphar SynCore Q3 2023 Q3 2023

995,134 > 1,000,000

148,176 280,000

29

Corporate Social Responsibility

1. Host health forum, biotechnology camp. Create a platform to facilitate and cultivate the interaction of medical, academic, and biotechnology professionals

2. Continue to be a sponsor for Breast Cancer Foundation, Spinal Cord Injury Foundation, The Diabetes Association of the Republic of China (Taiwan), Taiwan Yilan Association of Diabetes Supporters, and Youngsun Culture & Education Foundation

3. Donate to the National Health Service and the Taiwan Cancer Foundation for new drug development and Medicaid

4. Co-found an “R&D Center for Age-related Macular Degeneration” with National Taiwan University Hospital, for early diagnosis and early detection of age-related macular degeneration

5. Long-term spon ~~sor of the street lights in Wanshan Village, Zhongshan Village and Rens~~ han Trail. A sponsor for tourist information center in Dongshan County

6. Sponsor nutritional supplements and vegetables to hospitals and medical personnel in Yilan County

7. Sponsored in remote villages, free clinics by Luodong Boai Hospital and co-sponsored with Taipei Zhongxiao Rotary Club breast cancer screenings

8. Sponsor Oxaliplatin to the National Institutes of Health to conduct an IIT trial for pancreatic cancer

9. Donate to Yilan County Dementia Care Service Association

30

Corporate Social Responsibility

Supports Education and Sports

1. Donate NTD 5 million over 5 years to Kaohsiung Medical University for students in need of financial assistance

2. Sinphar Group and Yilan County Government will jointly organize annual “Sinphar Yilan Marathon” for 3 years with a sponsorship of NTD 8 million

3. Sponsor financial aid program to students in need of financial assistance from National Taiwan University, Faculty of Pharmacy and offer internship opportunities

4. Provide internship for students from Kaohsiung Medical University, Taipei Medical University, Nat ~~ional Defense Medical Center, China Medical University and Chia Nan~~ University of Pharmacy & Science. Also provide scholarship for Kaohsiung Medical University and National Defense Medical Center

5. Long term sponsor for Yilan High School football team, Shunan Junior High School baseball team and the facilities for elementary schools in Dongshan Township

6. Set up a “Chiang Ku” Cultural Park, and signed a MOU with Yilan County to promote “Chiang Ku”

7. From 2020 to 2022 sponsored the Outstanding Award for Taitung Geng Yuan Cup Junior Baseball League 31

31

ESG Policy

==> picture [684 x 289] intentionally omitted <==

----- Start of picture text -----

E S G
1. Energy 1. Employee 1. Business
Management Benefits Management
2. Emission 2. Stakeholders 2. Risk Management
Reduction
3. Value Chain
3. Charity and
Management
3. Eco-friendly Education
----- End of picture text -----

Not just a slogan, we believe that through the above, we can see the efforts and hard work of the Sinphar Group in these areas, and we also believe that these can be the cornerstone for future development.

==> picture [720 x 341] intentionally omitted <==

==> picture [113 x 113] intentionally omitted <==

Q & A

33